HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014

• Amanda Häggblom,

  Affiliations Department of Infectious Diseases, County Council of Gävleborg, Gävle, Sweden, Unit of Infectious diseases, Department of Medicine Huddinge, Karolinska Institute, Sweden

  ⨯
• Stefan Lindbäck,

  Affiliation Janssen Nordics, Solna, Stockholm, Sweden

  ⨯
• Magnus Gisslén,

  Affiliation Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

  ⨯
• Leo Flamholc,

  Affiliation Department of Infectious Diseases, Malmö University Hospital, Malmö, Sweden

  ⨯
• Bo Hejdeman,

  Affiliation Department of Infectious Diseases, Venhälsan-Södersjukhuset, Stockholm, Sweden

  ⨯
• Andreas Palmborg,

  Affiliation Janssen Nordics, Solna, Stockholm, Sweden

  ⨯
• Amy Leval,

  Affiliation Janssen Nordics, Solna, Stockholm, Sweden

  ⨯
• Eva Herweijer,

  Affiliation Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

  ⨯
• Sverrir Valgardsson,

  Affiliation Janssen Nordics, Solna, Stockholm, Sweden

  ⨯
• Veronica Svedhem

  * E-mail: veronica.svedhem-johansson@karolinska.se

  Affiliations Unit of Infectious diseases, Department of Medicine Huddinge, Karolinska Institute, Sweden, Department of Infectious Diseases, Karolinska University Hospital, Huddinge, Sweden

  ⨯